| Expression pattern: |
DN |
| Associated gene: |
IGF2R, AGO2 |
| Associated microRNA: |
miR-143-3p |
| Biological function: |
Protects against insulin resistance, promotes glucose uptake/insulin sensitivity, and inhibits lipid (triglyceride) deposition/accumulation in MetS models. |
| Molecular mechanism: |
Acts as a ceRNA/miRNA sponge for miR-143-3p, thereby regulating the miR-143-3p downstream target IGF2R and impacting insulin signaling (Akt phosphorylation). |
| Biological pathway or process: |
PI3K/AKT (promotes); glucose uptake (promotes); lipid metabolism (inhibits); ceRNA regulation (other) |
| Detected method: |
Q
S
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; circRIP; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; Flow Cytometry（Non-apoptosis/cycle）; Oil Red O Staining; Western Blot; In Vivo Animal Model; H&E Staining; Bioinformatics Analysis; Clinical Sample Validation |
| Clinical significance: |
Decreased serum/urine circRNF111 is linked to insulin resistance and dyslipidemia; circRNF111 is an independent protective factor for insulin resistance and hypertriglyceridemia. |
| Description: |
CircRNF111 is down-regulated in MetS serum/urine and acts protectively against insulin resistance and lipid deposition. It mainly functions as a cytoplasmic ceRNA that sponges miR-143-3p, relieving repression of IGF2R and supporting insulin signaling (Akt phosphorylation), improving glucose uptake and reducing triglyceride accumulation; this was supported by in vitro hADSC assays and HFD-induced obese mouse experiments. |
| Confidence score: |
0.8476 |